Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Methods at Treatment of Acute Migraine Attack in the Emergency Department

PHASE4CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

March 14, 2021

Study Completion Date

March 14, 2021

Conditions
Migraine Disorders
Interventions
DRUG

Lidocaine Hydrochloride

While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch

DRUG

Placebo

There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.

Trial Locations (1)

34890

Kartal Dr. Lutfi Kırdar City Hospital, Istanbul

All Listed Sponsors
lead

Dr. Lutfi Kirdar Kartal Training and Research Hospital

OTHER_GOV

NCT04491474 - Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Methods at Treatment of Acute Migraine Attack in the Emergency Department | Biotech Hunter | Biotech Hunter